Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hayato Mikuni"'
Autor:
Kazuhiko Oka, Akihiro Hasegawa, Hayato Mikuni, Ryosuke Miyazaki, Tomotaka Kumamoto, Yasuhiro Takeda, Natsuko Ukai, Takako Kiyokawa, Osamu Samura, Aikou Okamoto
Publikováno v:
Case Reports in Women's Health, Vol 40, Iss , Pp e00559- (2023)
Background: Small intestinal arteriovenous (AV) malformations may cause gastrointestinal hemorrhage, occasionally leading to anemia; however, they are rarely seen in pregnancy. This report presents a case of a pregnant woman who had recurrent severe
Externí odkaz:
https://doaj.org/article/e0fa85197bca47fb8efbb7567b9cd823
Publikováno v:
Expert Opinion on Biological Therapy. :1-7
Introduction: Esophageal cancer (EC) is the seventh most common cancer and the sixth leading cause of cancer death worldwide. The prognosis for advanced EC patients remains poor and there are few effective therapeutic agents available. Nivolumab is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ee370a4b07672d08f03f08139bd2ed
https://doi.org/10.1080/14712598.2021.1904887
https://doi.org/10.1080/14712598.2021.1904887
Autor:
Hayato, Mikuni, Narikazu, Boku
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 48(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a30a3c27c99d6ede750e30d1dfdaeaf
https://pubmed.ncbi.nlm.nih.gov/34521789
https://pubmed.ncbi.nlm.nih.gov/34521789
Autor:
Yusuke Nagata, Katsushi Amano, Hayato Mikuni, Tomohiro Kano, Masashi Ishikawa, Utako Ishimoto, Takashi Nishimura, Masaaki Noguchi, Ryoichi Sawada, Tomonori Imakita, Masahisa Ohkuma, Hiroaki Aoki, Eijiro Nagasaki, Makoto Kosuge, Atsushi Hokari, Masaichi Ogawa, Ken Eto, Masayuki Saruta
Publikováno v:
Journal of Clinical Oncology. 40:48-48
48 Background: The benefit of adjuvant chemotherapy with oxaliplatin for elderly patients with colorectal cancer (CRC) remains controversial. Our study could not demonstrate the benefit of adding oxaliplatin for elderly CRC patients aged over 70 year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee5d4597155b941fd29f2d2e34d3dc92
https://doi.org/10.1200/jco.2022.40.4_suppl.048
https://doi.org/10.1200/jco.2022.40.4_suppl.048
Autor:
Hayato Mikuni, Shun Yamamoto, Ryoichi Sawada, Yoshitaka Honma, Shigeki Sekine, Junya Oguma, Masayuki Saruta, Hiroyuki Daiko, Ken Kato, Koshiro Ishiyama
Publikováno v:
Journal of Clinical Oncology. 40:289-289
289 Background: Based on the results of the ATTRACTION-3 trial, nivolumab has shown superiority compared to taxane monotherapy as second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) patients (pts). However, the PD-L1 expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d68780a4893bc992b87697993f10f3c
https://doi.org/10.1200/jco.2022.40.4_suppl.289
https://doi.org/10.1200/jco.2022.40.4_suppl.289
Autor:
Hayato Mikuni, Ken Kato, Shun Yamamoto, Hirokazu Shoji, Hidekazu Hirano, Atsuo Takashima, Satoru Iwasa, Narikazu Boku, Kotoe Oshima, Natsuko Okita, Yoshitaka Honma
Publikováno v:
Annals of Oncology. 32:S298
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a0c928c50a82bb584da458c5472afe2
https://doi.org/10.1016/j.annonc.2021.05.572
https://doi.org/10.1016/j.annonc.2021.05.572
Autor:
Atsuo Takashima, Narikazu Boku, Ken Kato, Hidekazu Hirano, Shun Yamamoto, Natsuko Okita, Satoru Iwasa, Hayato Mikuni, Kotoe Oshima, Hirokazu Shoji, Yoshitaka Honma
Publikováno v:
Journal of Clinical Oncology. 39:179-179
179 Background: Based on the results of the ATTRACTION-1 and ATTRACTION-3 trials, nivolumab monotherapy has used for the treatment of metastatic or recurrence esophageal cancer patients who were refractory or intolerant to fluoropyrimidine and platin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::889b449b66b2e685208c0782d10976c5
https://doi.org/10.1200/jco.2021.39.3_suppl.179
https://doi.org/10.1200/jco.2021.39.3_suppl.179
Autor:
Tomohiro Kano, Hayato Mikuni, Masaaki Noguchi, K. Nakatsuka, Masashi Ishikawa, C. Kinoshita, Masayuki Saruta, Yusuke Nagata, Utako Ishimoto, Ryoichi Sawada, K. Harada, Katsushi Amano, Takashi Nishimura
Publikováno v:
Annals of Oncology. 30:ix64
Background The combination of gemcitabine and nab-paclitaxel (GnP) has been established as the first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (M-PC). However, the efficacy of the therapy in pts with borderline resectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1902dc4c074c40e8681e1a1aa7947097
https://doi.org/10.1093/annonc/mdz422.067
https://doi.org/10.1093/annonc/mdz422.067
Autor:
Utako Ishimoto, Ken Eto, Eijiro Nagasaki, Ryoichi Sawada, Tomohiro Kano, Hayato Mikuni, Masayuki Saruta, Masahisa Ohkuma, Takashi Nishimura, Katsuhiko Yanaga, Masaaki Noguchi, Kentaro Harada, Katsushi Amano, Yusuke Nagata, Masashi Ishikawa
Publikováno v:
Annals of Oncology. 30:vi118
Background Fluoropyrimidine (Fp) is one of the key drugs of chemotherapy in unresectable colorectal cancer (CRC), and usually used not only in first-line but also in second-line as beyond progression. The efficacy in combination of irinotecan, oxalip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bc22cf07f79fcf1fd835b69bc6740c8
https://doi.org/10.1093/annonc/mdz343.001
https://doi.org/10.1093/annonc/mdz343.001